Expansion Nears Completion in Switzerland

CSL Behring validates new production capacity in Bern.

CSL Delivers Net Profit of Over $2.1 Billion

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a reported net profit after tax of $2,103 million (1) for the 12 months en…

New partner for BaseLaunch

CSL Behring to become latest partner in BaseLaunch Phase II

Careful Steps Into a New Normal

One of CSL Behring's newest innovation centers in Bern, Switzerland, springs back to full life, with COVID-19 precautions in …

Bern's contribution against COVID-19

CSL Behring in Bern manufactures the hyperimmune for the pivotal Phase III clinical trial.

In Fight Against COVID-19

CSL Behring now evaluating 5 approaches to preventing and treating COVID-19.

Welcome back Stadium Wankdorf

CSL Behring is proud stadium partner of BSC YB!

Get a Look Inside Protinus

CSL Behring in Bern has made major progress on a large expansion project Protinus at its manufacturing facility.

CSL Behring to Acquire Biotech Company Vitaeris

Builds on CSL Behring’s promise and commitment to the transplant community